Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

103.03USD
12:39pm EDT
Price Change (% chg)

$-0.41 (-0.40%)
Prev Close
$103.44
Open
$103.60
Day's High
$103.72
Day's Low
$102.92
Volume
466,996
Avg. Vol
1,816,531
52-wk High
$106.74
52-wk Low
$85.50

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies located in 60 countries, including the United States, which sell products... (more)

Overall

Beta: 0.59
Market Cap (Mil.): $291,730.50
Shares Outstanding (Mil.): 2,820.29
Dividend: 0.70
Yield (%): 2.71

Financials

  JNJ.N Industry Sector
P/E (TTM): 19.12 32.67 33.58
EPS (TTM): 5.41 -- --
ROI: 14.72 18.00 17.30
ROE: 21.06 18.64 18.05
Search Stocks

Healthcare: A remedy for long-term investors

CHICAGO - (The opinions expressed here are those of the author, a columnist for Reuters.)

04 Aug 2014

COLUMN-Healthcare: A remedy for long-term investors

(The opinions expressed here are those of the author, a columnist for Reuters.)

04 Aug 2014

J&J seeks return of device seen as possibly raising cancer risk

- Johnson & Johnson said on Wednesday it plans to ask doctors to return its power morcellators, a controversial surgical device that may inadvertently spread cancer in women being treated for uterine growths called fibroids.

30 Jul 2014

J&J seeks return of device seen as possibly raising cancer risk

July 30 - Johnson & Johnson said on Wednesday it plans to ask doctors to return its power morcellators, a controversial surgical device that may inadvertently spread cancer in women being treated for uterine growths called fibroids.

30 Jul 2014

Europe backs new leukemia drugs from J&J and Gilead

LONDON - Two new leukemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months.

25 Jul 2014

Europe backs new leukaemia drugs from J&J and Gilead

LONDON, July 25 - Two new leukaemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months.

25 Jul 2014

BRIEF-EU medicines agency backs new drugs from Novo Nordisk, J&J, Gilead

July 25 - The European Medicines Agency: * EU medicines agency says recommends Novo Nordisk diabetes

25 Jul 2014

US STOCKS-Wall St dips after Yellen comments on valuations

* New York manufacturing hits highest level since April 2010

15 Jul 2014

J&J beats forecasts, helped by new hepatitis C drug

- Johnson & Johnson reported higher-than-expected quarterly results on sizzling sales of its new Olysio treatment for hepatitis C, but company officials cautioned the pill will lose steam later this year as newer rivals come to market.

15 Jul 2014

UPDATE 3-J&J beats forecasts, helped by new hepatitis C drug

July 15 - Johnson & Johnson reported higher-than-expected quarterly results on sizzling sales of its new Olysio treatment for hepatitis C, but company officials cautioned the pill will lose steam later this year as newer rivals come to market.

15 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Wright Reports
$75.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks